Business Wire

Amadeus Redefines Travel Advertising to Help Brands Capture Demand Earlier

28.5.2026 13:00:00 CEST | Business Wire | Press Release

Share

Amadeus today introduced the Amadeus Travel Advertising Platform at its Advertising Summit in Nice, France. Leveraging Accenture’s agentic framework for campaign execution, the platform outlines a new approach designed to help travel companies make faster, smarter advertising decisions based on where demand is forming — not just where it has already converted.

Travel advertising has become increasingly complex, fragmented across channels and often driven by historical performance signals that arrive too late to capture emerging demand. As travelers plan trips across AI chatbots, search, social, metasearch, content platforms and OTAs long before booking, travel brands face rising acquisition costs and growing pressure to prove return on investment.

The Amadeus Travel Advertising Platform connects forward-looking travel demand intelligence with advertising planning, activation and AI-supported decision-making. This enables travel brands to drive profitable demand and decisions by investing earlier, allocating budgets more efficiently and operating with clearer performance outcomes in a fragmented advertising ecosystem.

For travelers and travel agents, this approach delivers more relevant and timely experiences, connecting the right offers, content, and options at the moment they are making decisions.

From reactive optimization to demand-led orchestration

Most advertising solutions optimize performance within individual platforms or closed ecosystems. The Amadeus Travel Advertising Platform is designed to orchestrate advertising activity across channels, acting as a neutral execution layer that connects trusted travel data with cross-channel advertising decisions.

By acting earlier and more precisely, travel brands can reach travelers with more relevant messages at moments that better reflect their intent.

At the core of the platform is an intelligence layer that evaluates campaign performance holistically and applies AI to support cross-channel decision-making at scale. In line with Amadeus’ broader AI approach, automation is designed to enhance human strategy, ensuring decisions remain transparent, controllable and outcome-driven.

“Travel advertising has become more complex, but much of the decision-making is still reactive,” says Dan Ciocoiu, Head of Advertising Solutions at Amadeus. “This platform is about helping travel brands act earlier — using AI to support better decisions and connect demand insight to coordinated action across channels, while maintaining the trust, neutrality and control the industry expects from Amadeus.”

What is live today

The first live capability within the platform is the Omnichannel Budget Allocator, which is already used by Amadeus Advertising teams as part of managed services.

The Omnichannel Budget Allocator uses AI to continuously evaluate campaign performance and automatically reallocate advertising budgets across channels and campaigns, based on defined objectives such as bookings or return on ad spend. Rather than replacing native optimization tools from platforms such as Google and Meta, it complements them by orchestrating spend across the broader advertising mix, while applying guardrails to ensure responsible and stable decision‑making.

Designed to evolve with the travel ecosystem

The Amadeus Travel Advertising Platform is a platform designed to evolve over time. Future phases will expand capabilities, including deeper integration of forward-looking travel demand signals into decision‑making, enhanced measurement and reporting, and additional campaign management tools — with AI continuing to reinforce the platform’s ability to operate at scale across the travel ecosystem.

As part of this evolution, Amadeus is collaborating with Accenture to codevelop elements of the campaign management layer, accelerating time-to-market while allowing Amadeus to focus on its core differentiation: trusted travel data, orchestration and optimization at scale. Accenture brings complementary industry, media, technology and data expertise to enhance the platform, contributing its Accenture Media Console (AMC), which works to optimize performance across digital advertising platforms with an easy-to-use agentic interface, allowing the user to focus on strategy, not just administration.

“This is the next exciting chapter in our longstanding collaboration with Amadeus as a reinvention partner for the travel industry,” comments Tyson Wipperling, Managing Director, Travel at Accenture. “By bringing together Accenture’s industry, marketing, media and AI‑at‑scale capabilities through our Accenture Media Console, with the breadth and depth of Amadeus’ traveler intent and attribution data, we’re enabling a new approach to travel advertising: one that puts humans firmly in the lead, while AI does the heavy analytical lifting.”

Today, the platform underpins Amadeus Advertising’s managed services for hotel customers, with destinations and airlines having access to the capabilities soon.

By shifting the focus from reactive optimization to demand-led orchestration, the Amadeus Travel Advertising Platform helps travel companies operate with greater clarity, speed and efficiency — while remaining grounded in measurable performance outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260528366454/en/

Contacts

Laura Cobbold, Corporate External Communications, Amadeus.
laura.cobbold@amadeus.com
+34609141695

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press Release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press Release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye